María Fernández-Argüeso1, Eider Pascual-Corrales1, Nuria Bengoa Rojano1, Ana García Cano2, Lucía Jiménez Mendiguchía2, Marta Araujo-Castro3. 1. Endocrinology and Nutrition Department, Ramón y Cajal University Hospital & Instituto de Investigación Biomédica Ramón y Cajal (IRYCIS), Madrid, Spain. 2. Biochemical Department, Ramón y Cajal University Hospital, Madrid, Spain. 3. Endocrinology and Nutrition Department, Ramón y Cajal University Hospital & Instituto de Investigación Biomédica Ramón y Cajal (IRYCIS), Madrid, Spain. marta.araujo@salud.madrid.org.
Abstract
PURPOSE: To study the differences in the prevalence, risk, and grade of control of different cardiometabolic comorbidities in patients with primary aldosteronism (PA) and essential hypertension (EH) matched by age, sex, and blood pressure levels at diagnosis. METHODS: Case-control study of a secondary base (PA patients in follow-up in a tertiary hospital between 2018 and 2020). Controls were patients with non-functioning adrenal incidentalomas and EH, matched by age, sex, and baseline diastolic blood pressure (DBP) and systolic blood pressure (SBP). RESULTS: Fifty patients with PA and 50 controls were enrolled in the study. At diagnosis, PA patients had a higher prevalence of chronic kidney disease (CKD) than controls (18.4% vs. 2.1%, P = 0.008). No differences were detected in the prevalence of other cardiometabolic comorbidities nor in their degree of control (P > 0.05). All patients received antihypertensive medical treatment and 10 PA patients underwent unilateral laparoscopic adrenalectomy. After a median follow-up of 31.9 [IQR = 1.0-254.8] months, PA patients presented a greater degree of declination of kidney function than controls (average decrease in glomerular filtration rate (MDRD-4) -17.6 ± 3.1 vs. -2.8 ± 1.8 ml/min/1.73 m2, P < 0.001). There were no differences in the grade of SBP (P = 0.840) and DBP control (P = 0.191), nor in the risk of developing other comorbidities or in their degree of control. CONCLUSIONS: PA patients have a higher prevalence of CKD at the time of diagnosis when compared to EH matched by age, sex, and blood pressure levels. Furthermore, the risk of kidney function impairment throughout the follow-up is significantly greater in PA patients and is independent of the degree of blood pressure control.
PURPOSE: To study the differences in the prevalence, risk, and grade of control of different cardiometabolic comorbidities in patients with primary aldosteronism (PA) and essential hypertension (EH) matched by age, sex, and blood pressure levels at diagnosis. METHODS: Case-control study of a secondary base (PA patients in follow-up in a tertiary hospital between 2018 and 2020). Controls were patients with non-functioning adrenal incidentalomas and EH, matched by age, sex, and baseline diastolic blood pressure (DBP) and systolic blood pressure (SBP). RESULTS: Fifty patients with PA and 50 controls were enrolled in the study. At diagnosis, PA patients had a higher prevalence of chronic kidney disease (CKD) than controls (18.4% vs. 2.1%, P = 0.008). No differences were detected in the prevalence of other cardiometabolic comorbidities nor in their degree of control (P > 0.05). All patients received antihypertensive medical treatment and 10 PA patients underwent unilateral laparoscopic adrenalectomy. After a median follow-up of 31.9 [IQR = 1.0-254.8] months, PA patients presented a greater degree of declination of kidney function than controls (average decrease in glomerular filtration rate (MDRD-4) -17.6 ± 3.1 vs. -2.8 ± 1.8 ml/min/1.73 m2, P < 0.001). There were no differences in the grade of SBP (P = 0.840) and DBP control (P = 0.191), nor in the risk of developing other comorbidities or in their degree of control. CONCLUSIONS: PA patients have a higher prevalence of CKD at the time of diagnosis when compared to EH matched by age, sex, and blood pressure levels. Furthermore, the risk of kidney function impairment throughout the follow-up is significantly greater in PA patients and is independent of the degree of blood pressure control.
Authors: R Rossi; L Tauchmanova; A Luciano; M Di Martino; C Battista; L Del Viscovo; V Nuzzo; G Lombardi Journal: J Clin Endocrinol Metab Date: 2000-04 Impact factor: 5.958
Authors: Z Somlóová; J Widimský; J Rosa; D Wichterle; B Strauch; O Petrák; T Zelinka; J Vlková; M Masek; J Dvoráková; R Holaj Journal: J Hum Hypertens Date: 2010-06-24 Impact factor: 3.012
Authors: Paul Milliez; Xavier Girerd; Pierre-François Plouin; Jacques Blacher; Michel E Safar; Jean-Jacques Mourad Journal: J Am Coll Cardiol Date: 2005-04-19 Impact factor: 24.094
Authors: John W Funder; Robert M Carey; Franco Mantero; M Hassan Murad; Martin Reincke; Hirotaka Shibata; Michael Stowasser; William F Young Journal: J Clin Endocrinol Metab Date: 2016-03-02 Impact factor: 5.958
Authors: Marta Araujo-Castro; Miguel Paja Fano; Marga González Boillos; Begoña Pla Peris; Eider Pascual-Corrales; Ana María García Cano; Paola Parra Ramírez; Patricia Martín Rojas-Marcos; Jorge Gabriel Ruiz-Sanchez; Almudena Vicente Delgado; Emilia Gómez Hoyos; Rui Ferreira; Iñigo García Sanz; Patricia Díaz Guardiola; Juan Jesús García González; Carolina M Perdomo; Manuel Morales; Felicia A Hanzu Journal: Endocrine Date: 2022-03-11 Impact factor: 3.925
Authors: Xiao Lin; Muhammad Hasnain Ehsan Ullah; Xiong Wu; Feng Xu; Su-Kang Shan; Li-Min Lei; Ling-Qing Yuan; Jun Liu Journal: Front Cardiovasc Med Date: 2022-02-02